Persistence on anti-TNF therapy - data from Serbian National Spondyloarthritis Registry

Persistence on anti-TNF therapy - data from Serbian National Spondyloarthritis Registry

Introduction/Objective. The aim of our study was to retrospectively analyze data about efficacy and persistence on different anti-TNFα treatment in spondyloarthritis (SpA). Methods. We retrospectively analyzed SpA patients whose data were entered into the Serbian national SpA registry. All patients...

Full description

Bibliographic Details
Main Authors:	Cvetković Jovana, Živanović-Radnić Tatjana, Vojinović Jelena, Stojanović Sonja, Stamenković Bojana, Veselinović Mirjana, Erdeljan Biljana, Atanasković Marija, Veličković Zoran
Format:	Article
Language:	English
Published:	Serbian Medical Society 2023-01-01
Series:	Srpski Arhiv za Celokupno Lekarstvo
Subjects:	anti-tnfα drugs anti-tnfα switch registry spondyloarthritis
Online Access:	https://doiserbia.nb.rs/img/doi/0370-8179/2023/0370-81792200121C.pdf

Similar Items

Different Therapeutic Response to Anti-TNF Drugs in Patients with Axial Spondyloarthritis Depending on Their Clinical Profile: An Unsupervised Cluster Analysis
by: Carmen Priego-Pérez, et al.
Published: (2024-03-01)

Thrombocytosis in patients with spondyloarthritis: a case–control study
by: Linan Deng, et al.
Published: (2023-03-01)

The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study
by: Kui Zhang, et al.
Published: (2021-09-01)

The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding
by: Katarzyna Romanowska-Próchnicka, et al.
Published: (2021-03-01)

TNF-α in Uveitis: From Bench to Clinic
by: Qi Jiang, et al.
Published: (2021-11-01)

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial
by: Désirée van der Heijde, et al.
Published: (2018-03-01)

Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates
by: Stephanie Harvard, et al.
Published: (2017-09-01)

Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses
by: Silvia Menegatti, et al.
Published: (2019-03-01)

High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis
by: Liseth de Wolff, et al.
Published: (2023-10-01)

ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS
by: Claudia Deaconu, et al.
Published: (2016-09-01)

Behҫet’s Disease, and the Role of TNF-α and TNF-α Blockers
by: Tim van der Houwen, et al.
Published: (2020-04-01)

Correlation of serum subfatin, cthrc1, ctrp3, ctrp6 levels with disease indices in patients with axial spondyloarthritis
by: İ.Merve B. Uçar, et al.
Published: (2023-09-01)

Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials
by: Damien Roche, et al.
Published: (2021-07-01)

Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice
by: Maria Esposito, et al.
Published: (2019-07-01)

Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis
by: Atzeni F, et al.
Published: (2021-05-01)

OPTIMIZING EXISTING TOOLS FOR REACHING AN ADEQUATE DISEASE CONTROL IN PATIENTS WITH SPONDYLOARTHRITIS
by: Claudia Deaconu, et al.
Published: (2016-06-01)

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS
by: S. A. Lapshina, et al.
Published: (2016-09-01)

Critical role of tumor necrosis factor-α in the early process of wound healing in skin
by: Masae Ritsu, et al.
Published: (2017-01-01)

Can anti-TNFα Antibodies Affect SARS-CoV-2 Disease Outcomes?
by: Mohammad Reza Khazdair
Published: (2022-05-01)

Pesquisa de autoanticorpos em pacientes com artrite psoriásica sob terapia anti-TNFα
by: Vilma S Trindade Viana, et al.

Biomarcadores clínicos de Remisión en pacientes con Artritis Reumatoide tratados con Anti-TNFα
by: Isabel Acosta Colman, et al.
Published: (2015-07-01)

Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
by: Jordi Gratacós, et al.
Published: (2019-01-01)

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
by: Abdullah Sakkat, et al.
Published: (2022-03-01)

Association of TNF-alpha polymorphism (-308 A/G) with high activity of rheumatoid arthritis and therapy response to etanercept
by: Marinković Milena, et al.
Published: (2011-01-01)

Study of the association between the polymorphism of the TNF-α gene and prostate cancer
by: Tatiana Pardo, et al.
Published: (2019-06-01)

Anti-tumor necrosis factor-α is potentially better than tumor necrosis factor-α as the biomarker for sarcopenia: Results from the I-Lan longitudinal aging study
by: Wei-Ju Lin, et al.
Published: (2023-02-01)

Etanercept in axial spondyloarthritis – treatment efficacy
by: I. Z. Gaydukova, et al.
Published: (2022-03-01)

Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
by: Salvatore D’Angelo, et al.
Published: (2022-07-01)

Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR
by: Walter P. Maksymowych, et al.
Published: (2021-01-01)

Impact of TNF-α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis
by: Olivia Patsalos, et al.
Published: (2020-04-01)

Merkel cell carcinoma in a young female on infliximab
by: Alex Harrison, DO, et al.
Published: (2022-09-01)

Demyelinating Disease Following Anti-TNFa Treatment (Adalimumab) in Patients with psoriasis: A Case Report (PP-13)
by: Mohammadreza Malek Zadeh
Published: (2023-01-01)

Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
by: Rosita Saraceno, et al.
Published: (2013-09-01)

Dual Blockade of TNF and IL-17A Inhibits Inflammation and Structural Damage in a Rat Model of Spondyloarthritis
by: Ihsan Hammoura, et al.
Published: (2022-01-01)

A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis
by: Zong HX, et al.
Published: (2022-08-01)

Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy
by: Gian Marco Leone, et al.
Published: (2023-02-01)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα
by: Júlio César Bertacini de Moraes, et al.

Funding Innovation Thanks to Anti-TNF-α Biosimilars Uptake: The Economic Impact in Italy
by: Massimiliano Povero, et al.
Published: (2020-05-01)

Positive experience with TNF-α inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids
by: Ekaterina A. Nikitina, et al.
Published: (2023-07-01)

Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort
by: Regula Neuenschwander, et al.
Published: (2020-10-01)